CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Memphasys Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Memphasys Ltd
30 Richmond Rd
Phone: +61 284157300p:+61 284157300 HOMEBUSH WEST, NSW  2140  Australia Ticker: MEMMEM

Business Summary
Memphasys Limited is an Australia-based reproductive biotechnology company. The Company is engaged in developing novel medical devices, diagnostics, and media with applications to assisted reproduction technology (ART) in humans and animals. Its reproductive biotechnology products in development include medical devices, in vitro diagnostics, and new proprietary media. The Company's product pipeline includes Felix, ROSA, and AI-Port. The Felix is a patented, automated device for quickly separating high quality sperm from semen for use in human in vitro fertilization (IVF) procedures without causing damage to DNA. Felix has a sizable target market worldwide. The Company’s ROSA is an in vitro diagnostic that assesses semen and blood samples for the presence of oxidative stress. The AI-Port stores and transports animal semen for artificial insemination (AI) for up to four days without the harmful effects of freezing sperm used in standard AI procedures in livestock.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20236/30/2023Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board RobertCooke 62 4/26/2022 4/26/2022
Acting Chief Executive Officer, Executive Director DavidAli 11/29/2023 11/29/2023
Director of Finance PabloNeyertz
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
PrIME Biologics Pte Ltd 30 NA Singapore

Business Names
Business Name
InqSep Inc.
Kaogen Pty Ltd.
KaoSep Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 24 (As of 6/30/2008)
Outstanding Shares: 1,130,630,958 (As of 12/31/2023)
Shareholders: 2,142
Stock Exchange: ASX
Fax Number: +61 284157399


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024